En las noticias
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting.
New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
The combination of two drugs used to boost immune response could shrink tumours in 60 per cent of patients, according to the new research by Anglia Ruskin University.
Immunotherapies break into cold colorectal cancers at ASCO
Several immuno-oncology mechanisms on display at this year’s ASCO help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.
Royalty deals on the rise as Ligand takes stake in Agenus' success
Part of a growing trend in the industry, Ligand Pharmaceuticals (Nasdaq: LGND) has inked a royalty financing agreement with immunology company Agenus (Nasdaq: AGEN).
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200